Fulcrum Therapeutics (FULC) Change in Receivables (2020 - 2025)
Fulcrum Therapeutics (FULC) reported Change in Receivables of -$979000.0 for Q2 2025, down 141.96% year-over-year from $2.3 million in Q2 2024, and up 12.35% quarter-over-quarter from -$1.1 million in Q1 2025.
Fulcrum Therapeutics (FULC) Change in Receivables (2020 - 2025) Analysis & Trends
Fulcrum Therapeutics (FULC) has 6 years of Change in Receivables data on file, last reported at -$979000.0 in Q2 2025.
- Change in Receivables for Q2 2025 came in at -$979000.0, down 141.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$979000.0 (down 200.0% YoY), and the FY2025 annual result was -$2.1 million, down 234.45% from the prior year.
- Change in Receivables advanced to -$979000.0 in Q2 2025 per FULC's latest filing, from -$1.1 million in the prior quarter.
- Over five years, Change in Receivables peaked at $2.6 million in Q3 2021 and troughed at -$2.8 million in Q4 2022.
- A 5-year average of -$124882.4 and a median of -$130000.0 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables slumped 9083.87% in 2022, then jumped 1840.79% in 2024.
- A 5-year view of Change in Receivables shows it stood at -$31000.0 in 2021, then tumbled by 9083.87% to -$2.8 million in 2022, then soared by 98.49% to -$43000.0 in 2023, then tumbled by 3527.91% to -$1.6 million in 2024, then soared by 37.24% to -$979000.0 in 2025.
- Business Quant data shows FULC's Change in Receivables at -$979000.0 in Q2 2025, -$1.1 million in Q1 2025, and -$1.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -4.08 Mn |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -979,000.00 |
| Jun 30, 2025 | -979,000.00 |
| Mar 31, 2025 | -1.12 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Dec 31, 2024 | -1.56 Mn |
| Dec 31, 2024 | -1.56 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | -537,000.00 |
| Mar 31, 2024 | -537,000.00 |
| Dec 31, 2023 | -43,000.00 |
| Dec 31, 2023 | -43,000.00 |
| Sep 30, 2023 | -76,000.00 |
| Sep 30, 2023 | -76,000.00 |
| Jun 30, 2023 | 557,000.00 |
| Jun 30, 2023 | 557,000.00 |
| Mar 31, 2023 | -130,000.00 |
| Mar 31, 2023 | -130,000.00 |